Mizuho raises Arcutis Biotherapeutics stock price target to $26 on Zoryve sales
PositiveFinancial Markets

Mizuho has raised its stock price target for Arcutis Biotherapeutics to $26, driven by strong sales of their product Zoryve. This adjustment reflects confidence in the company's growth potential and the effectiveness of Zoryve in treating skin conditions. Investors are likely to view this as a positive sign for the company's future, indicating that Arcutis is on the right track to capitalize on its market opportunities.
— Curated by the World Pulse Now AI Editorial System